Monthly infusions of an investigational product that encapsulates dexamethasone sodium phosphate into autologous erythrocytes (EryDex) appeared safe but did not significantly improve neurological ...

Affecting the nervous system, immune system and other body organs, ataxia telangiectasia is characterized with uncoordinated movements of the individual suffering from this disorder. The secondary ...

Regulatory submissions planned in the US, Europe, and other jurisdictions for levacetylleucine in Ataxia-Telangiectasia, a neurodegenerative disease without any approved treatment and impacting ...

IMMUNOLOGIC abnormalities, including hypogammaglobulinemia, abnormalities of gamma 1 A globulin, poor homograft rejection and structural abnormalities of the thymus gland, have recently been reported ...

In the phase 3 NEAT trial, eDSP was well tolerated but did not significantly reduce neurological symptoms in patients with ataxia-telangiectasia. Topline data were announced from a phase 3 trial ...

Levacetylleucine significantly improves neurological symptoms and functioning in patients with ataxia-telangiectasia, according to results from the IB1001-303 clinical trial. Topline results were ...

Aston University bioscientist Dr John Reynolds has won a £125,000 Springboard grant from the Academy of Medical Sciences (AMS) for research into neurodegeneration caused by a rare genetic disease.

New research lends insight into the pathogenesis of neurodegeneration in Ataxia telangiectasia. Ataxia telangiectasia (A-T) is a rare, genetic immunodeficiency disease that affects multiple organ ...

Only successful pivotal Phase III trial in Ataxia-Telangiectasia (A-T), a rare, progressive neurodegenerative disease with no approved treatments Phase III trial successfully achieved its primary ...

A-T (ataxia telangiectasia) is an autosomal recessive genetic disease caused by mutations in the ATM gene 1,2,3,4. Clinically, A-T patients are characterized by progressive childhood cerebellar ataxia ...